Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024
February 01 2024 - 2:00AM
UK Regulatory
Genflow Biosciences Plc
("Genflow" or "the Company")
LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The
Company (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field
of longevity research developing therapeutics that potentially halt
or slow the ageing process, is pleased to provide a year-end review
and summary of its progress during 2023 and defined strategic
priorities for 2024.
The Company achieved many significant
accomplishments throughout the year across all aspects of its
business. The full year-end review can be viewed on Genflow’s
website:
https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/.
Key 2023 Highlights:
- Genflow expanded its intellectual
property portfolio with a provisional patent application for
editing the SIRT6 gene, linked to longevity and age-related
diseases.
- Began trading on the OTCQB Venture
Market in the US under the ticker GENFF, aligned to its US-focused
strategy.
- Genflow received positive feedback
from the Federal Agency for Medicines and Health Products in
Belgium on the design of Phase I/II clinical trials for its lead
drug candidate, GF-1002, in NASH patients.
- Genflow made several key
appointments, including Capital Plus Partners Ltd as Joint Broker
in order to access both institutional and international investment;
Harbor Access for investor relations support; and Prof. Dr. Sven
Francque, an expert in nonalcoholic fatty liver disease and Prof.
Dr. Mary E. Rinella, a fatty liver disease specialist to its
Scientific Advisory Board.
Strategic Priorities in
2024:
- Genflow awarded 2.89 million Euros
in two new grants that will broaden its research pipeline and
expand the size of its therapeutic markets over the next three
years. (Refer to press release:
https://www.globenewswire.com/news-release/2024/01/18/2811445/0/en/Genflow-Biosciences-Partners-with-Revatis-SA-and-EXO-Biologics-in-Groundbreaking-Aging-Research-Fueled-by-Two-Major-Research-Grants.html)
- Genflow to undertake key
Investigational New Drug (IND)-enabling development activities that
will help define the pharmacological and toxicological properties
of its lead drug candidate, GF-1002, and its potential benefits for
NASH patients.
- Initial site selection and QMS
framework for clinical readiness, expected by the end of 2025 for
the NASH program.
- Commence preliminary discussions
with the European Medicines Agency (EMA) on Mechanism of Action
(MoA) data for Orphan Drug Application (ODA) for our second
compound GF-3001, targeting Werner Syndrome.
- Select Contract Development and
Manufacturing Organization (CDMO) for advancing the GMP
manufacturing of the NASH clinical lot of lead drug candidate,
GF-1002.
- Develop and implement project
management, budgeting and governance for collaborative partners, in
line with clinical and pre-clinal activities that will enable IND
applications.
- Moving key patent applications
under the Patent Cooperation Treaty (PCT) to the national phase,
while further expanding our development pipeline with new products
and new indications.
Dr. Eric Leire, CEO of Genflow commented: “The
milestones we reached in 2023 were numerous, and I commend our team
for their exceptional commitment to execution and delivery. While
2023 was a pivotal year, we’re poised for an even stronger 2024, as
we shift focus to scaling development of our lead drug candidate,
GF-1002, and its potential benefits for NASH patients. With the
support of our partners and the backing of new grants, we are
poised to make meaningful advancements in the field of
longevity.”
Contacts
Genflow Biosciences |
Harbor Access |
Dr Eric Leire, CEO |
Jonathan Paterson, Investor Relations |
+32-477-495-881 |
+1 475 477 9401 |
|
Jonathan.Paterson@Harbor-access.com |
|
|
Joint Corporate Brokers |
|
Clear Capital Markets |
Capital Plus Partners Ltd |
Bob Roberts, +44 203 869 6080 |
Dominic Berger, +44 203 821
6167 |
|
Keith Swann, +44 0203 821
6169 |
|
Jon Critchley, +44 0203 821
6168 |
|
|
About Genflow Biosciences
Established in 2020, Genflow Biosciences Ltd is
a UK-based biotechnology company, with R&D facilities in
Belgium, developing and researching potential novel therapeutics
that halt or slow the ageing process enabling society to live
longer, healthier lives. Genflow Biosciences’ lead compound GF-1002
works through the delivery of a centenarian variant of the SIRT6
gene, which has yielded promising preclinical results. Genflow
Biosciences expects to commence a clinical trial in 2024 to study
the potential benefit of GF-1002 in non-alcoholic steatohepatitis
(NASH) for which there are few or no approved therapies. By
treating ageing as a risk factor to disease, Genflow Biosciences
aims to reduce the financial, emotional, and social costs of an
ageing population. For more information: www.genflowbio.com
DISCLAIMER
The contents of this announcement have been
prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking
statements. The forward-looking statements include, but are
not limited to, statements regarding the Company's or the
Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to
projections, forecasts or other characterisations of future events
or circumstances, including any underlying assumptions, is a
forward-looking statement. The words "anticipate", "believe",
"continue", "could", "estimate", "expect", "intend", "may",
"might", "plan", "possible", "potential", "predict", "project",
"seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the
absence of these words does not mean that a statement is not
forward-looking.
Forward-looking statements include all matters
that are not historical facts. Forward-looking statements are based
on the current expectations and assumptions regarding the Company,
the business, the economy and other future conditions. Because
forward-looking statements relate to the future, by their nature,
they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking
statements are not guarantees of future performance and the
Company's actual financial condition, actual results of operations
and financial performance, and the development of the industries in
which it operates or will operate, may differ materially from those
made in or suggested by the forward-looking statements contained in
this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the
industries in which it operates or will operate, are consistent
with the forward-looking statements contained in this announcement,
those results or developments may not be indicative of financial
condition, results of operations or developments in subsequent
periods. Important factors that could cause actual results to
differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social,
business, technological, competitive, market and regulatory
conditions.
Any forward-looking statement contained in this
announcement applies only as of the date of this announcement and
is expressly qualified in its entirety by these cautionary
statements. Factors or events that could cause the Company's actual
plans or results to differ may emerge from time to time, and it is
not possible for the Company to predict all of them. The Company
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained in this announcement to reflect any change in its
expectations or any change in events, conditions or circumstances
on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law,
the Prospectus Regulation Rules, the Listing Rules, the Disclosure
Guidance and Transparency Rules of the FCA or the UK Market Abuse
Regulation.
This information is provided by RNS, the news
service of the London Stock Exchange. RNS is approved by the
Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or
visit www.rns.com.
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From May 2024 to Jun 2024
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From Jun 2023 to Jun 2024